TargetMol

Fosgonimeton acetate

Product Code:
 
TAR-T39507L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T39507L-1mg1mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39507L-5mg5mg£405.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39507L-10mg10mg£568.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39507L-1mL1 mL * 10 mM (in DMSO)£630.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39507L-25mg25mg£864.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39507L-50mg50mg£1,139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39507L-100mg100mg£1,508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Fosgonimeton aceate is an agonist of hepatocyte growth factor (HGF).
CAS:
0
Formula:
C29H49N4O10P
Molecular Weight:
644.69
Pathway:
Tyrosine Kinase/Adaptors
Purity:
0.9705
SMILES:
O=C(N[C@@H]([C@@H](C)CC)C(NCCCCCC(N)=O)=O)[C@@H](NC(CCCCC)=O)CC1=CC=C(OP(O)(O)=O)C=C1.CC(O)=O
Target:
c-Met/HGFR

References

Xue Hua, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413.